Inactive Instrument
Sprint Bioscience AB Share Price Nasdaq Stockholm
Stocks
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq Stockholm
|
||
| - | - |
|
| Market Cap | 29Cr 2.96Cr 2.96Cr 2.57Cr 2.42Cr 2.2Cr 4.12Cr 283.74Cr 4.15Cr 11Cr 143.94Cr 11Cr 11Cr 457.62Cr | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 29Cr 2.96Cr 2.96Cr 2.57Cr 2.42Cr 2.2Cr 4.12Cr 283.74Cr 4.15Cr 11Cr 143.94Cr 11Cr 11Cr 457.62Cr | EV / Sales 2026 * |
3.33x | EV / Sales 2027 * | 2.99x |
| Free-Float |
72.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Johan Emilsson
CEO | Chief Executive Officer | 42 | 01/10/2023 |
Martin Andersson
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/01/2009 |
| Director of Finance/CFO | 55 | 04/05/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 01/01/2010 | |
Fredrik Lehmann
BRD | Director/Board Member | 50 | 01/01/2019 |
| Chairman | 58 | 01/01/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +5.04% | +3.66% | +50.62% | +103.77% | 7.02TCr | ||
| -0.67% | -0.39% | +35.17% | +75.89% | 6.26TCr | ||
| -3.18% | -0.78% | -14.14% | +369.82% | 2.74TCr | ||
| -0.16% | -0.49% | +26.31% | +11.75% | 2.57TCr | ||
| +2.20% | -4.72% | +2.19% | -13.14% | 2.48TCr | ||
| -0.64% | -2.49% | +18.66% | -20.88% | 1.95TCr | ||
| -7.03% | -10.19% | +161.91% | +303.00% | 1.55TCr | ||
| -4.45% | -5.78% | -9.67% | +482.03% | 1.47TCr | ||
| +4.96% | +4.63% | -2.75% | +864.40% | 1.47TCr | ||
| Average | -0.43% | -1.83% | +29.81% | +241.85% | 3.06TCr | |
| Weighted average by Cap. | +0.60% | -0.80% | +31.97% | +167.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.68Cr 88.88L 88.88L 77.01L 72.68L 65.93L 1.24Cr 85Cr 1.25Cr 3.34Cr 43Cr 3.34Cr 3.26Cr 137.39Cr | 9.68Cr 99.12L 99.12L 85.89L 81.05L 73.53L 1.38Cr 95Cr 1.39Cr 3.73Cr 48Cr 3.72Cr 3.64Cr 153.22Cr |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















